Patents Examined by Thomas Cunningham
-
Patent number: 5583031Abstract: The invention features an isolated sample of mammalian class II major histocompatibility heterodimers which are membrane-associated or in soluble form, and which are capable of binding added antigenic peptide; methods for producing large amounts of the soluble or membrane-associated histocompatibility protein by expression of DNA encoding the .alpha. and .beta. polypeptides; and methods for loading these heterodimers with any desired antigen.Type: GrantFiled: February 6, 1992Date of Patent: December 10, 1996Assignee: President and Fellows of Harvard CollegeInventor: Lawrence J. Stern
-
Patent number: 5538724Abstract: Methods and compositions are described for modulating trafficking of leukocytes to endothelial cells involving the binding of homing receptors and addressins. Particularly, compositions are provided which can inhibit the interaction between the homing receptor and addressin or provide for directing specific molecules associated with diagnosis or treatment, where the molecules bind to the addressins.Type: GrantFiled: December 19, 1991Date of Patent: July 23, 1996Assignee: The Board of Trustees for the Leland Stanford Junior Univ.Inventors: Eugene C. Butcher, Philip R. Streeter, Ellen L. Berg
-
Patent number: 5516515Abstract: Two distinct alpha interferon receptor proteins have been separated and partially purified by antigen affinity chromatography and SDS-PAGE. These proteins are potentially useful as therapeutic agents. Antibodies against these proteins are potentially useful as diagnostic and therapeutic agents.Type: GrantFiled: May 3, 1990Date of Patent: May 14, 1996Assignee: Interferon Sciences, Inc.Inventors: Laura C. Vellucci, Steven R. Scott, Mei-June Liao, Douglas Testa
-
Patent number: 5500215Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.Type: GrantFiled: November 3, 1994Date of Patent: March 19, 1996Assignee: The Biomembrane InstituteInventor: Sen-itiroh Hakomori
-
Patent number: 5422428Abstract: Antigenic surface proteins from the intraerythrocytic merozoite stage of Babesia bigemina have been isolated using cell fusions and monoclonal antibodies produced thereby. The gene encoding a 58 kD surface protein has been identified and the DNA sequence determined and compared with sequences of other known merozoite proteins. Immunization of mammals, such as bovines, with purified isolates induces an immunological response that is effective to reduce pathological effects of babesiosis induced by Babesia bigemina. Diagnostic kits using monoclonal antibodies and antigenic surface proteins of Babesia bigemina are also disclosed.Type: GrantFiled: December 6, 1991Date of Patent: June 6, 1995Assignee: Washington State UniversityInventors: Travis C. McGuire, Terry F. McElwain, Lance E. Perryman, William C. Davis
-
Patent number: 5403919Abstract: Novel antibodies that recognize endothelial cell surface molecules and block leukocyte extravasation are provided. These antibodies recognize tissue-specific endothelial cell surface molecules and block lymphocyte migration from the blood into tissues such as mucosal lymphoid organs and peripheral lymph nodes. Novel endothelial cell surface proteins involved in leukocyte extravasation and having a molecular weight of approximately 58,000 to 69,000 daltons and express a tissue-specific determinant are also described. The antibodies are used in an immunotherapeutic method to treat individuals having a disease or inflammation-associated pathology in which leukocyte extravasation plays a role.Type: GrantFiled: March 3, 1993Date of Patent: April 4, 1995Assignee: Board of Trustees of the Leland Stanford Junior University Stanford UniversityInventor: Eugene C. Butcher
-
Patent number: 5395614Abstract: Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof.The invention relates to hybrid proteins composed of part-sequences of the malaria antigens HRPII and SERP. The HRPII sequence has already proven protective in the monkey model (EP-A2-0 315 085), where a C-terminal region of 189 amino acids has been used in the present invention in the same way as in the preceding protection experiment. SERP was identified with the aid of an antiserum against a protective protein band (EP-A1-0 283 882); the part-sequence used (amino acids (AA) 631-892 or 630-764) contains at least two T-cell epitopes (Roussilhon et al. (1990), Immunol. Letters 25, 149-154). In preferred embodiments, further T-cell epitope-containing regions of other P. falciparum proteins such as merozoite surface antigen I (MSA I or else "195 kd antigen"), amino acids from 100 to 300, are incorporated (Crisanti et al. (1988), Science 240, 324-326).Type: GrantFiled: November 16, 1993Date of Patent: March 7, 1995Assignee: Behringwerke AktiengesellschaftInventors: Bernhard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
-
Patent number: 5393523Abstract: Recombinant histidine-rich protein of Plasmodium falciparum, its preparation and use. It was possible, by screening two different Plasmodium falciparum cDNA gene banks with an antiserum against a 41 kD protein and by cross-hybridization with the insert DNA of a clone obtained therewith, to isolate a gene which codes for a Histidine-Alanine-rich protein (HRP-II). This protein protects aotus monkeys from infection with P. falciparum and is thus a suitable constituent of a malaria vaccine.Type: GrantFiled: August 20, 1993Date of Patent: February 28, 1995Assignee: Behringwerke AktiengesellschaftInventors: Bernard Knapp, Erika Hundt, Burkhard Enders, Hans Kupper
-
Patent number: 5389530Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.Type: GrantFiled: July 27, 1993Date of Patent: February 14, 1995Assignee: The Biomembrane InstituteInventor: Sen-itiroh Hakomori
-
Patent number: 5385888Abstract: Methods and compositions are provided for regulating surface membrane receptor response by modulating the interaction between an MHC Class I antigen and the surface membrane receptor. Various techniques may be employed for enhancing or reducing the interaction between the Class I antigen and surface membrane receptor, e.g., enhancing production of the Class I antigen.Type: GrantFiled: May 3, 1993Date of Patent: January 31, 1995Assignee: The Regents of the University of CaliforniaInventors: Robert S. Goodenow, Lennart Olsson
-
Patent number: 5374520Abstract: Assay methods and kits for detecting and quantifying anti-Epstein-Barr Virus ("EBV") antibodies in a sample. The methods comprise contacting samples with a free or immobilized synthetic antigenic EBV polypeptide that is recognized by human antibodies and detecting or quantifying immunocomplex formation. The polypeptides described are the carboxy-terminated one-third of the EBV Nuclear Antigen encoded by the EBV Bam H1 K-fragment (plasmid pNAK28), a 46-55 kDa EBV Early Antigen encoded by the 4340 base pair Bcl 1 to Bam H1 restriction fragment within the EBV Bam H1 M-fragment (plasmid pEAD), and an EBV viral capsid antigen. Bacterially synthesized fusion proteins are recognized by human anti-EBV antibodies. The assay method is diagnostic for infectious mononucleosis, chronic mononucleosis, Burkett's lymphoma and monopharyngeal carcinoma.Type: GrantFiled: July 15, 1993Date of Patent: December 20, 1994Assignee: The Johns Hopkins UniversityInventor: Gregory Milman
-
Patent number: 5348740Abstract: This invention relates to polypeptide antigens of T.ovis suitable for use in vaccines to protect ruminants against infection by cestode parasites. The antigens are preferably obtained by expression of DNA coding therefor in a recombinant host cell. Aspects of the invention include DNA encoding the antigens, vectors containing the DNA and hosts which express the antigens.The invention also provides antibody and DNA probes for use in identifying protective antigens of cestode parasites other than T.ovis.Type: GrantFiled: March 16, 1992Date of Patent: September 20, 1994Assignees: Coopers Animal Health NZ Ltd., University of Melbourne, Ministry of Agriculture & FisheriesInventors: Gavin B. L. Harrison, Robert P. Dempster, Michael D. Rickard, Marshall W. Lightowlers, Kim L. O'Hoy, Kevin S. Johnson, David D. Heath, Stephen B. Lawrence, Jennifer G. Vinton
-
Patent number: 5312810Abstract: Compositions comprising the C-terminal portion of adenylate cyclase stimulating factor (ACSF) are useful for making ACSF-specific antisera.Type: GrantFiled: November 13, 1992Date of Patent: May 17, 1994Assignees: The University of Melbourne, Genentech, Inc.Inventors: William I. Wood, Thomas J. Martin
-
Patent number: 5310551Abstract: A method for inhibiting pulmonary oxygen toxicity in a patient requiring elevated levels of inhaled oxygen, by prophylactic administration of certain adhesion molecules and antibodies thereto.Type: GrantFiled: February 10, 1993Date of Patent: May 10, 1994Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Craig D. Wegner, L. Gordon Letts
-
Patent number: 5284931Abstract: Pharmaceutical compositions comprising antibodies to intercellular adhesion molecule-1 (ICAM-1 or CD54) are useful in methods of decreasing the severity of inflammation associated with the adhesion of leukocytes to cells bearing ICAM-1. Treatment with anti-ICAM-1 antibodies reduced the severity of inflammation associated with acute organ or tissue rejection and prolonged allograft survival time. Such compositions may optionally contain other immunsuppressive agents.Type: GrantFiled: April 27, 1990Date of Patent: February 8, 1994Assignee: Dana Farber Cancer InstituteInventors: Timothy A. Springer, Robert Rothlein, Steven D. Marlin, Michael L. Dustin
-
Patent number: 5159063Abstract: A substantially pure, single chain plasma protein of approximately 120 kDa having an N-terminal amino acid sequence EKNGIDIYSLTD, and a mixture of protein fragments having vasodilatory activity which fragments are generated by activated Kallikrein cleavage of the 120 kDa protein.Type: GrantFiled: February 2, 1989Date of Patent: October 27, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Carl H. Hammer, Ruth M. Jacobs, Michael M. Frank
-
Patent number: 5019511Abstract: Monoclonal antibodies are disclosed that react with an antigenic polypeptide having a molecular weight of approximately 45,000 that is expressed in the cell membrane of P. falciparun-infected erythrocytes. The antibodies were raised using the Honduras CDC isolate, and can be used for diagnostic purposes. The hybridoma producing the monoclonal antibodies is also disclosed.Type: GrantFiled: April 14, 1988Date of Patent: May 28, 1991Inventors: Robert T. Reese, Harold A. Stanley